Volume 10, Number 5—May 2004
Research
Vancomycin Susceptibility within Methicillin-resistant Staphylococcus aureus Lineages
Robin A. Howe*, Alastair Monk†, Mandy Wootton*, Timothy R. Walsh‡, and Mark C. Enright†
Table
Characteristics of study isolates with reduced vancomycin susceptibilitya
| Genotype |
Clonal type | agr type | Vancomycin resistance phenotype (no. of strains) | PAP-AUC | Country of origin | Antimicrobial susceptibility*† |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CC | ST | SCCmec | Lzd | Syn | Gen | Cip | Rif | |||||
| 5 |
5 |
I |
EMRSA-3 |
II |
hVISA (1) |
0.98 |
UK |
S |
S |
R |
R |
R |
| I |
VISA (1) |
1.9 |
USA |
S |
S |
R |
R |
S |
||||
| 5 |
5 |
II |
New York/Japanese |
II |
hVISA (10) |
0.97–1.23 |
Japan, Sweden, France, Poland, UK, USA, Norway |
S |
S |
S/R |
S/R |
S/R |
| I or II |
VISA (3) |
1.4–1.92 |
USA |
S |
S |
S |
R |
S/R |
||||
| 5 |
5 |
IV |
Pediatric |
I or II |
hVISA (3) |
1.19–1.32 |
UK |
S |
S |
S |
S/R |
S/R |
| 5 |
5 |
NT |
I |
VISA (1) |
1.44 |
France |
S |
S |
R |
R |
R |
|
| 8 |
8 |
I |
II |
hVISA (3) |
0.92–1.32 |
France, UK, Norway |
S |
S |
R |
R |
R |
|
| 8 |
8 |
II |
Irish-1 |
II |
hVISA (3) |
1.04–1.2 |
France, USA, Norway |
S |
S |
S/R |
R |
S/R |
| 8 |
8 |
IV |
EMRSA-4, -6 |
I |
hVISA(11) |
0.94–1.24 |
France, USA |
S |
S/R |
S/R |
R |
S/R |
| 22 |
22 |
IV |
EMRSA-15 |
I or II |
hVISA (7) |
0.9–1.25 |
UK |
S |
S |
S |
R |
S/R |
| 25 |
25 |
NT |
I |
hVISA(1) |
1.13 |
UK |
S |
S |
R |
R |
R |
|
| 30 |
36 |
II |
EMRSA-16 |
II |
hVISA (3) |
0.92–1.17 |
UK |
S |
S |
R |
R |
R |
| 45 |
45 |
II |
I |
hVISA (1) |
1 |
USA |
S |
S |
R |
R |
S |
|
| 8 |
239 |
I or II |
Brazilian/Portuguese |
I or II |
hVISA (10) |
0.9–1.22 |
France, Poland, China, Norway, UK |
S |
S |
R |
S/R |
S/R |
| I |
VISA (3) |
1.44–3.01 |
France, Poland, UK |
S |
S/R |
R |
R |
S/R |
||||
| 8 |
239 |
NT |
I |
hVISA (1) |
0.92 |
France |
S |
S |
R |
R |
R |
|
| 8 |
246 |
NT |
I |
hVISA (1) |
1.13 |
Norway |
S |
S |
R |
R |
R |
|
| 8 | 247 | I | Iberian | I |
VISA (1) |
1.57 |
UK |
S |
S |
R |
R |
R |
| I or II | hVISA (37) | 0.9–1.33 | France, Poland, UK, Norway | S | S | R | R | S/R | ||||
aS, susceptible; R, resistant; NT, nontypeable; PAP-AUC, population analysis profiling followed by measuring the area under the curve; Lzd, linezolid; Syn, synercid; Gen, gentamicin; Cip, ciprofloxacin; Rif, rifampin; CC, clonal complex; ST, sequence type; EMRSA, methicillin-resistant Staphylococcus aureas found in the United Kingdom (UK) ; hVISA, heterogeneous vancomycin-intermediate S. aureus; USA, United States of America.
Page created: February 22, 2011
Page updated: February 22, 2011
Page reviewed: February 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.